Citation Impact
Citing Papers
A Phase II Study of the Efficacy and Safety of the Combination Therapy of the MEK Inhibitor Refametinib (BAY 86-9766) Plus Sorafenib for Asian Patients with Unresectable Hepatocellular Carcinoma
2014
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Differential Serum Levels of Eosinophilic Eotaxins in Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, and Autoimmune Hepatitis
2013 StandoutNobel
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
The Spring α-Helix Coordinates Multiple Modes of HCV (Hepatitis C Virus) NS3 Helicase Action
2016 StandoutNobel
A prospective randomized trial of ceftazidime versus netilmicin plus mezlocillin in the empirical therapy of presumed sepsis in cirrhotic patients
1997
Myeloid-derived suppressor cells coming of age
2018 Standout
Acute kidney injury
2012 Standout
Global epidemiology and genotype distribution of the hepatitis C virus infection
2014
Hepatocellular carcinoma
2016 Standout
Hepatocellular carcinoma
2018 Standout
Calcineurin Inhibitor Nephrotoxicity
2009 Standout
Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence
2018
Microwave ablation for the treatment of hepatocellular carcinoma that met up-to-seven criteria: feasibility, local efficacy and long-term outcomes
2017
The influence of continuous seven-day elevated intra-abdominal pressure in the renal perfusion in cirrhotic rats
2003
Role of Antioxidants and Natural Products in Inflammation
2016 Standout
Comparison of the efficacy of octreotide, vasopressin, and omeprazole in the control of acute bleeding in patients with portal hypertensive gastropathy: A controlled study
2002
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
2017
Diagnosis and Management of Autoimmune Hepatitis
2010
Calcineurin inhibitor‐sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity
2007
Hepatocellular carcinoma
2021 Standout
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
2015
The clinical and prognostic significance of CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients receiving radiotherapy
2016
Oxidative stress modulation in hepatitis C virus infected cells
2015
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
2021
Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe
2016
Pyroptosis: mechanisms and diseases
2021 Standout
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial
2016
Comparison of Long-Term Survival of Patients with BCLC Stage B Hepatocellular Carcinoma after Liver Resection or Transarterial Chemoembolization
2013
Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit
2021
The Noninvestigational Use of Tyrosine Kinase Inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring
2012
Global burden of liver disease: 2023 update
2023 Standout
Systematic Review of Randomized Trials on Vasoconstrictor Drugs for Hepatorenal Syndrome
2009
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
2014 Standout
The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy
2017
Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document
2000 Standout
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
2015
Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH)
2019
Relationship Between Activation of the Sympathetic Nervous System and Renal Blood Flow Autoregulation in Cirrhosis
2007
Molecular therapies and precision medicine for hepatocellular carcinoma
2018
Predictors of Response to Therapy With Terlipressin and Albumin in Patients With Cirrhosis and Type 1 Hepatorenal Syndrome
2009
A Randomized, Prospective, Double-Blind, Placebo-Controlled Trial of Terlipressin for Type 1 Hepatorenal Syndrome
2008
Results from the International Conference of Experts on Intra-abdominal Hypertension and Abdominal Compartment Syndrome. I. Definitions
2006 Standout
Sorafenib for the Treatment of Advanced Hepatocellular Cancer – a UK Audit
2016
Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
2018
Advances in the Diagnosis, Pathogenesis, and Management of Autoimmune Hepatitis
2010
Hepatocellular carcinoma
2022 Standout
Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
2017
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Hepatocellular Carcinoma
2019 Standout
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4
2015 StandoutNobel
Global Burden of Hepatitis C: Considerations for Healthcare Providers in the United States
2012
Sorafenib in Patients with Hepatocellular Carcinoma—Results of the Observational INSIGHT Study
2017
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
2007
Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
2013
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data
2016
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib
2014
Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years
2017 Standout
Cutting Edge: Chronic Inflammatory Liver Disease in Mice Expressing a CD28-Specific Ligand
2012 StandoutNobel
Animal models of autoimmune hepatitis
2010
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
2016 StandoutNobel
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis
2018 Standout
Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study
2015
Works of Lucy Dagher being referenced
Regional differences in sorafenib‐treated patients with hepatocellular carcinoma: GIDEON observational study
2016
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON
2016
Variceal bleeding and portal hypertensive gastropathy
2001
First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non-interventional study
2012
Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation
2003
Genetic contribution of major histocompatibility complex class II region to type 1 autoimmune hepatitis susceptibility in Venezuela
2007
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
2016
The hepatorenal syndrome
2001
Final analysis of GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma [HCC] and of Its Treatment with Sorafenib [Sor]) in >3000 Sor-treated patients (pts): Clinical findings in pts with liver dysfunction.
2013
P0372 : Gideon: A retrospective analysis of prognostic factors for survival
2015
Latin American Association for the Study of the Liver (LAASL) Clinical Practice Guidelines: Management of Hepatocellular Carcinoma
2014
2013
Trends and projections of hepatitis C virus epidemiology in Latin America
2011
Treatment of Intermediate/Advanced Hepatocellular Carcinoma in the Clinic: How Can Outcomes Be Improved?
2010